ClinicalTrials.gg
RecruitingNCT07848152ASSEE-SHDUpdated Sep 29, 2026

Active Surveillance and Safety/Efficacy Evaluation of Innovative Devices for Structural Heart Disease Intervention

An observational study in Transcatheter Mitral Valve Edge-to-Edge Repair System and Biodegradable Patent Foramen Ovale Closure Device, sponsored by Shanghai Jiao Tong University School of Medicine. Recruiting at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Shanghai Jiao Tong University School of Medicine · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Foramen Ovale, Patent with a site in China — 13 open to participants now, 13 under way, none of them phase 3. Foramen Ovale, Patent · China.

Started
2025
with 1 other
Observational
6 of 20
5 open now
Primary completion
2029-01
later than 12 of 12 live
Registered
20th of 20
by date

Among the 20 studies in Foramen Ovale, Patent with a site in China, this one is one of 2 that started in 2025, is one of 6 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 20th registered.

Foramen Ovale, Patent

137 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.

Browse Foramen Ovale, Patent studies →

Open to participants now

13 of the 20 studies in Foramen Ovale, Patent with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 34 Foramen Ovale, Patent studies recruiting now, 11 (32%) set no upper age limit and 19 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Foramen Ovale, Patent with a site in China, or all of them as a file.
02

Study summary

This study aims to establish an active surveillance system to evaluate the safety and effectiveness of innovative medical devices used in the interventional treatment of structural heart disease. The devices of interest include a biodegradable patent foramen ovale (PFO) closure device and a transcatheter mitral valve edge-to-edge repair system. Clinical information from patients receiving these devices during routine clinical care will be collected and analyzed. The findings will help evaluate the safety and effectiveness of these devices and support the development of appropriate clinical evaluation indicators and long-term monitoring strategies.

03

Conditions studied

  • Transcatheter Mitral Valve Edge-to-Edge Repair System
  • Biodegradable Patent Foramen Ovale Closure Device

Browse trials for

Keywords

  • Patent Foramen Ovale Closure Device
  • Transcatheter Mitral Valve Edge-to-Edge Repair
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  1. Biodegradable PFO Closure Device Cohort: Patients with confirmed PFO-associated ischemic stroke who undergo implantation of a biodegradable PFO closure device.
  2. Transcatheter Mitral Valve Edge-to-Edge Repair (TEER) Cohort: Patients with functional or degenerative mitral regurgitation who undergo transcatheter mitral valve edge-to-edge repair using a TEER system.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients undergoing implantation of a biodegradable PFO closure device.
  2. Patients undergoing transcatheter mitral valve edge-to-edge repair.

Exclusion criteria

Exclusion Criteria:

The participant expresses a desire to withdraw from the study.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,200 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Biodegradable Patent Foramen Ovale Closure Device

    Participants with patent foramen ovale (PFO) who receive a biodegradable PFO closure device as part of routine clinical care will be included in this cohort. Clinical data will be collected to evaluate the safety and effectiveness of the device during follow-up.

  • Transcatheter Mitral Valve Edge-to-Edge Repair System Cohort

    Participants with degenerative or functional mitral regurgitation who undergo transcatheter mitral valve edge-to-edge repair using a transcatheter mitral valve edge-to-edge repair system. Safety and effectiveness outcomes will be assessed during follow-up.

06

What researchers measure

Primary outcomes

  1. Incidence of Major Adverse Events

    Incidence of major adverse events related to the biodegradable PFO closure or transcatheter mitral valve edge-to-edge repair procedure during follow-up.

    Time frame: At 1, 6, and 12 months after the procedure

  2. Anatomical success of PFO closure within 12 months after biodegradable PFO occluder implantation, assessed by transthoracic echocardiography

    The proportion of participants achieving successful anatomical closure of the patent foramen ovale (PFO) during the 12-month follow-up period after biodegradable PFO occluder implantation, assessed by transthoracic echocardiography.

    Time frame: At 1, 6, and 12 months after the procedure

  3. Incidence of the composite clinical outcome of heart failure hospitalization, all-cause mortality, or cardiovascular mortality within 12 months after transcatheter edge-to-edge mitral valve repair

    The proportion of participants experiencing at least one of the following events during the 12-month follow-up period after TEER: hospitalization for heart failure, all-cause death, or cardiovascular death. Events will be assessed through clinical follow-up and review of medical records.

    Time frame: At 1, 6, and 12 months after the procedure

Secondary outcomes

  1. Degree of device degradation

    The degree of degradation of the biodegradable PFO closure device will be assessed by echocardiography during follow-up.

    Time frame: At 1, 6, and 12 months after the procedure

  2. Incidence of residual shunt after PFO closure

    The presence of residual shunt after implantation of the biodegradable PFO closure device will be assessed by echocardiography with contrast study, when applicable.

    Time frame: At 1, 6, and 12 months after the procedure.

  3. Incidence of re-intervention after PFO closure

    The percentage of participants requiring reapeat intervention or surgical treatment related to the PFO closure device during follow-up.

    Time frame: At 1, 6, and 12 months after the procedure.

  4. Incidence of recurrent stroke after PFO closure

    The occurrence of recurrent ischemic or hemorrhagic stroke during the follow-up period will be assessed by clinical evaluation and review of medical records.

    Time frame: At 1, 6, and 12 months after the procedure.

  5. Incidence of device-related thrombosis after PFO closure

    The occurrence of thrombosis related to the biodegradable PFO closure device during follow-up will be assessed by echocardiography and clinical assessment.

    Time frame: At 1, 6, and 12 months after the procedure.

  6. Proportion of participants who underwent TEER and achieved immediate procedural success

    Immediate procedural success is defined as successful completion of the transcatheter mitral valve edge-to-edge repair procedure with post-procedural mitral regurgitation (MR) grade ≤2+, as assessed by echocardiography.

    Time frame: Within 24 hours after the procedure.

  7. Incidence of subsequent open-heart surgery in the TEER group

    The number of participants undergoing subsequent open-heart surgery related to TEER during follow-up.

    Time frame: At 1, 6, and 12 months after the procedure.

  8. Incidence of ischemic or hemorrhagic stroke in the TEER group

    The occurrence of ischemic or hemorrhagic stroke during follow-up in the TEER group will be assessed by clinical evaluation and review of medical records.

    Time frame: At 1, 6, and 12 months after the procedure.

  9. Incidence of bleeding events in the TEER group

    The occurrence of bleeding events during follow-up in the TEER group will be assessed by clinical evaluation and review of medical records.

    Time frame: At 1, 6, and 12 months after the procedure.

07

Study locations

3 of 11 sites recruiting
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu, China
    Recruiting
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Xiaotong Wen · Contact1127337995@qq.com · +86 18123548072
    • Caojin Zhang · Principal investigator
  • Fuwai Central China Cardiovascular Hospital
    Zhengzhou, Henan, China
    Recruiting
    • Menghao Li · Contactedward564@163.com · +86 18790660032
    • Shubo Song · Principal investigator
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei, China
    Recruiting
    • Lei Wang · Contact119559295@qq.com · +86 18702797617
    • Gangcheng Zhang · Principal investigator
  • General Hospital of Northern Theater Command, Chinese People's Liberation Army
    Shenyang, Liaoning, China
    Not yet recruiting
    • Jiawang Xiao · Contactxjw492918837@126.com · +86 17790991821
    • Qiguang Wang · Principal investigator
  • Shandong Provincial Hospital
    Jinan, Shandong, China
    Not yet recruiting
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan, China
    Not yet recruiting
    • Xuechun Sun · Contactsunxchun@163.com · +86 18981838108
    • Yunshan Cao · Principal investigator
  • Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences/Affiliated Cardiovascular Hospital of Kunming Medical University
    Kunming, Yunnan, China
    Not yet recruiting
    • Kairui Yang · Contact416719379@qq.com · +86 13987313055
    • Cheng Wang · Principal investigator
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, China
    Not yet recruiting
  • FUWAI Hospital, CAMS&PUMC
    Beijing, China
    Not yet recruiting
    • Jing Dong · ContactDjing0324@163.com · +86 15810174302
    • Guangzhi Zhao · Principal investigator
  • East Hospital, Tongji University
    Shanghai, China
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant-level data relevant to the study objectives, including baseline characteristics, procedural data, safety and efficacy outcomes, and follow-up data, will be shared.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Start Date: 12 months after publication of the primary results End Date: No end date

Access criteria: De-identified individual participant-level data and supporting information will be available to qualified researchers upon reasonable request and subject to review and approval by the study investigators. Access will be provided for scientifically justified research purposes in accordance with applicable regulations and data protection requirements. Requests should be submitted to the study investigators, and approved data will be shared through a secure data transfer mechanism.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jan 2029, 37 months after the start.

Of 29 observational studies under Foramen Ovale, Patent, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 92. This study's planned 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartActual
Dec 30, 2025
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jan 31, 2029
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848152
Collaborators
Chinese Academy of Medical Sciences, Fuwai Hospital, Guangdong Provincial People's Hospital, LanZhou University, Shandong Provincial Hospital, Beijing Anzhen Hospital, Sichuan Provincial People's Hospital, Zhongnan Hospital, Shanghai East Hospital of Tongji University, ScienTech Medical, Valgen Medtech, The General Hospital of Northern Theater Command
Responsible party
Lijun Fu (Chief Physician, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Sep 29, 2026
Start date
Dec 30, 2025
Primary completion
Jan 31, 2029 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

Xinyi Xu
Contact
3342@scmc.com.cn
+86 18930830756
Kai Wang
Contact
30192@scmc.com.cn
+86 15317921903
Lijun Fu
principal investigator · Shanghai Children's Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion